Standardized Neurologic Assessment Documentation for Daily Nelarabine Administration: A Bedside Questionnaire

Area of Science:

• Pediatric Oncology
• Neuro-oncology
• Patient Safety

Background:

• Nelarabine is crucial for treating pediatric T-cell lymphoblastic malignancies.
• High-grade neurologic toxicities are rare but serious adverse events associated with nelarabine.
• Early detection and discontinuation of nelarabine can mitigate poor patient outcomes.

Purpose of the Study:

• To implement and evaluate a novel neurologic assessment tool for early identification of nelarabine-induced neurotoxicity.
• To improve the documentation of neurotoxicity assessments during nelarabine treatment courses.

Main Methods:

• A 7-question neurologic assessment tool was developed and implemented for daily use during nelarabine therapy.
• The tool was prospectively utilized in 31 pediatric patients over an 18-month period.
• Documentation rates and instances of neurotoxicity identification leading to dose omission were tracked.

Main Results:

• The implementation of the neurologic assessment tool significantly improved documentation rates from 65.9% to 97.2%.
• Early identification of neurotoxicity led to the omission of nine nelarabine doses.
• The tool facilitated timely interventions, optimizing patient management.

Conclusions:

• The novel neurologic assessment tool is effective in enhancing early detection of nelarabine neurotoxicity in pediatric patients.
• Routine implementation of this tool can improve patient safety and optimize treatment management for T-cell lymphoblastic malignancies.
• Standardizing neurotoxicity assessment is vital for effective nelarabine therapy.